Novel Pharmaceutical(新药)研究综述
Novel Pharmaceutical 新药 - Advances in the development of new antibiotics and other novel pharmaceuticals are also discussed. [1] INTRODUCTION: Noninferiority or equivalence testing are often used when comparing a novel pharmaceutical, operation, or procedure to the current standard designated as safe. [2] Utilizing this standardized model, the efficacy and the tissue impact of novel pharmaceuticals can be investigated in detail with respect to cell morphology, behavior, viability as well as gene expression profiles thereby providing a 3D hydrogel tumor stroma a model that is of great interest for the pharmaceutical industry. [3] However, most of the deliberations for developing effective pharmaceuticals proved inconsequential, thereby encouraging the identification of new pathways, and novel pharmaceuticals for capping the COVID‐19 infection. [4] To combat the serious threat of rising AMR, it is crucial to develop strategies for robust surveillance, use of new/novel pharmaceuticals, and prevention of antibiotic misuse. [5] Although these novel pharmaceuticals show promise for slowing disease progression, they are primarily effective in the early stages of amyloidosis, underscoring the importance of early diagnosis. [6] Novel pharmaceuticals targeting this tumor-specific isoform have entered clinical trials, but the effect of genetic or transcriptomic background on the effectiveness of these drugs is unknown. [7] Further research is warranted to explore the impact of novel pharmaceuticals on quality of life for children with SMA longitudinally to optimize clinical and psychosocial outcomes. [8] The discovery and development of novel pharmaceuticals is an area of active research mainly due to the large investments required and long payback times. [9] Collectively, these findings demonstrate the existence of an anti-apoptotic multi-drug resistant pool of cancer cells in CLL patients, and validates a novel pharmaceutically tractable pathway to deplete this reservoir. [10] This may be due to new transfusion guidelines and the introduction of novel pharmaceuticals such as tranexamic acid. [11] Recent scientific investigations focused on drug discovery have accelerated the demand for novel pharmaceutical and agricultural products which are closely correlated with industrial applications. [12] PURPOSE/OBJECTIVE(S) Despite the promise of improving the therapeutic ratio of radiation with novel pharmaceuticals, the last drug to receive FDA approval for use in combination with radiation was over 15 years ago. [13] Such studies highlight important strategies for designing and tuning the interaction efficacy of novel pharmaceuticals at molecular level. [14] Background Clinical trials of novel pharmaceuticals in Rheumatoid Arthritis routinely use strict inclusion/exclusion criteria aimed at selecting a defined homogeneous population and producing a non-confounded demonstration of the agent’s clinically relevant pharmacologic effect. [15] Predicting the metabolic fate of drugs is very important to prevent drug-drug interactions in the development of novel pharmaceuticals. [16] BACKGROUND The launch of novel pharmaceuticals in the developing world faces significant barriers that can delay or ultimately inhibit uptake. [17] They can also serve as highly useful pre-clinical testing tools to develop safer genetically modified wheat, hypoallergenic wheat products, novel pharmaceuticals, and vaccines. [18] As such, brain network organisation can potentially be employed as an important neurocognitive trait to enhance statistical power of genetic studies in ADHD and as a surrogate efficacy endpoint in the development of novel pharmaceuticals. [19] ConclusionsThe majority of industry research payments to SOs are related to novel pharmaceuticals, which highlights the expanding influence SOs play in systemic therapies. [20] Increasing knowledge on rare genetically determined channelopathies can contribute to the development of novel pharmaceuticals since ion channels are central players in the processing of pain. [21] Their inherent structural complexity and natural diversity might hold the key to efficiently address the urgent need for the development of novel pharmaceuticals. [22] Synthetic peptides derived from naturally occurring host defence peptides (HDPs) have garnered significant attention as novel pharmaceuticals, particularly as alternatives to antibiotics and for immunomodulatory applications. [23] The transient receptor potential ankyrin 1 (TRPA1) ion channel is expressed in pain-sensing neurons and other tissues and has become a major target in the development of novel pharmaceuticals. [24] Atrial fibrillation (AF) is a frequent cardiovascular entity (almost 33 million subjects worldwide suffering from different forms of this entity) especially in developed countries [1] accompanied by poor quality of life and posing significant morbidity and mortality which may explain the increasing amount of research on ion and cells mechanisms, the identification of electric circuits and the introduction of novel pharmaceutical and invasive strategies. [25] Anatomic pathology and clinical pathology end points are standard components of almost every nonclinical general toxicity study conducted during the risk assessment of novel pharmaceuticals and chemicals. [26] BACKGROUND Several factors contribute to the development failure of novel pharmaceuticals, one of the most important being adverse effects in pre-clinical and clinical studies. [27] Unlike the introduction of novel pharmaceuticals, the introduction of novel neurosurgical procedures is not subject to formal oversight as it often occurs outside of formal research. [28] Why, then, do we limit their access to the range of studies available to the public? Prisoners in the United States historically were subjected to testing of known toxins, such as radioactive isotopes and chemical warfare agents, as well as novel pharmaceuticals (3). [29] Interestingly, the vast majority (87%) of payments were related to studies of novel pharmaceuticals and not surgical devices. [30]还讨论了新抗生素和其他新型药物的开发进展。 [1] 简介：在将一种新的药物、操作或程序与指定为安全的当前标准进行比较时，通常使用非劣效性或等效性测试。 [2] 利用这种标准化模型，可以详细研究新型药物的功效和组织影响，包括细胞形态、行为、活力以及基因表达谱，从而提供 3D 水凝胶肿瘤基质模型，该模型对制药业。 [3] 然而，大多数开发有效药物的审议被证明是无关紧要的，从而鼓励确定新的途径和新的药物来限制 COVID-19 感染。 [4] 为了应对 AMR 上升的严重威胁，制定强有力的监测、使用新药/新型药物和预防抗生素滥用的战略至关重要。 [5] 尽管这些新型药物有望减缓疾病进展，但它们主要在淀粉样变性的早期有效，这凸显了早期诊断的重要性。 [6] 针对这种肿瘤特异性异构体的新型药物已进入临床试验，但遗传或转录组学背景对这些药物有效性的影响尚不清楚。 [7] 需要进一步研究以纵向探索新型药物对 SMA 儿童生活质量的影响，以优化临床和心理社会结果。 [8] 新型药物的发现和开发是一个活跃的研究领域，主要是由于所需的大量投资和较长的投资回报期。 [9] 总的来说，这些发现证明了在 CLL 患者中存在抗凋亡、多药耐药的癌细胞库，并验证了一种新的药物可处理途径来消耗该储存库。 [10] 这可能是由于新的输血指南和新型药物（如氨甲环酸）的引入。 [11] 最近以药物发现为重点的科学研究加速了对与工业应用密切相关的新型医药和农产品的需求。 [12] 目的/目标 尽管有望通过新型药物提高放射治疗的治疗率，但最后一次获得 FDA 批准与放射联合使用的药物是 15 年前。 [13] 这些研究强调了在分子水平上设计和调整新型药物相互作用功效的重要策略。 [14] 背景 类风湿性关节炎中新型药物的临床试验通常使用严格的纳入/排除标准，旨在选择明确的同质人群，并对药物的临床相关药理作用进行非混杂证明。 [15] 预测药物的代谢命运对于防止新药开发中的药物相互作用非常重要。 [16] 背景 在发展中国家推出新药面临着可能延迟或最终抑制吸收的重大障碍。 [17] 它们还可以作为非常有用的临床前测试工具，用于开发更安全的转基因小麦、低过敏性小麦产品、新型药物和疫苗。 [18] 因此，脑网络组织可能被用作重要的神经认知特征，以增强 ADHD 遗传研究的统计能力，并作为开发新药的替代功效终点。 [19] 结论 支付给 SOs 的大部分行业研究费用与新药有关，这凸显了 SOs 在全身治疗中所发挥的不断扩大的影响。 [20] 增加对罕见基因决定的通道病的了解有助于开发新型药物，因为离子通道是疼痛处理的核心参与者。 [21] 它们固有的结构复杂性和自然多样性可能是有效解决开发新型药物的迫切需求的关键。 [22] 源自天然存在的宿主防御肽 (HDP) 的合成肽作为新型药物，特别是作为抗生素的替代品和免疫调节应用，已引起了广泛关注。 [23] 瞬时受体电位锚蛋白 1 (TRPA1) 离子通道在痛觉神经元和其他组织中表达，已成为开发新型药物的主要靶点。 [24] 心房颤动 (AF) 是一种常见的心血管疾病（全世界近 3300 万受试者患有不同形式的这种疾病），尤其是在发达国家 [1]，伴随着较差的生活质量和显着的发病率和死亡率，这可能解释了心房颤动数量的增加。离子和细胞机制的研究，电路的识别以及新的药物和侵入性策略的引入。 [25] 解剖病理学和临床病理学终点是几乎所有在新药和化学品风险评估期间进行的非临床一般毒性研究的标准组成部分。 [26] 背景 有几个因素导致新药研发失败，其中最重要的因素之一是临床前和临床研究中的副作用。 [27] 与新型药物的引入不同，新型神经外科手术的引入不受正式监督，因为它经常发生在正式研究之外。 [28] 那么，为什么我们要限制他们访问公众可获得的研究范围呢？历史上，美国的囚犯接受了已知毒素的测试，例如放射性同位素和化学战剂，以及新型药物 (3)。 [29] 有趣的是，绝大多数（87%）的付款与新药研究有关，而不是与手术器械有关。 [30]
Develop Novel Pharmaceutical 开发新药
Substantial clinical and research efforts are being invested to develop novel pharmaceutical agents. [1] The results demonstrate that certain medicinal plants have a high antiviral potential and may serve as a lead to develop novel pharmaceutical agents to cure PED as well as the diseases caused by other coronaviruses. [2] Seaweeds are a major marine resource that can be explored to develop novel pharmaceutical molecules. [3] dysentrica, thereby advocating the need for further investigations in an endeavour to develop novel pharmaceuticals from this plant. [4] These findings help to explain why piperine is a weak agonist, and may guide future efforts to develop novel pharmaceutical reagents targeting TRPV1. [5]大量的临床和研究工作正投入到开发新的药剂中。 [1] 结果表明，某些药用植物具有很高的抗病毒潜力，可以作为开发新的药物来治疗 PED 以及其他冠状病毒引起的疾病的线索。 [2] 海藻是一种主要的海洋资源，可用于开发新型药物分子。 [3] 痢疾杆菌，因此主张需要进一步研究以努力从这种植物中开发新的药物。 [4] 这些发现有助于解释为什么胡椒碱是一种弱激动剂，并可能指导未来开发针对 TRPV1 的新型药物试剂的努力。 [5]
Developing Novel Pharmaceutical 开发新药
Background Developing novel pharmaceuticals demands substantial investment despite high uncertainty of success and ultimate market value. [1] Pharmacological reviews on medicinal plants will provide valuable information; thus, Cassia fistula L can provide important discoveries of valuable bioactive natural products facilitating in developing novel pharmaceuticals products. [2] Naturally occurring peptides provide a rich source of lead compounds for developing novel pharmaceuticals with high selectivity and potency. [3]背景 尽管成功和最终市场价值的不确定性很高，但开发新型药物需要大量投资。 [1] 药用植物的药理学评论将提供有价值的信息；因此，决明子瘘管可以提供有价值的生物活性天然产物的重要发现，有助于开发新的药物产品。 [2] nan [3]
Investigate Novel Pharmaceutical
Advanced in vitro models, which closely mimic critical aspects of the pathology, have emerged as valuable platforms to investigate novel pharmaceutical therapies for the treatment of SSc. [1] Current research in the field of ischemic stroke focuses on better understanding the pathophysiology of stroke, to develop and investigate novel pharmaceutical targets. [2]先进的体外模型密切模仿病理学的关键方面，已成为研究治疗 SSc 的新型药物疗法的宝贵平台。 [1] 目前缺血性中风领域的研究重点是更好地了解中风的病理生理学，以开发和研究新的药物靶点。 [2]
One Novel Pharmaceutical 一种新药
In 2020, one novel pharmaceutical agent for small animals, the ACTH analog tetracosactide for the assessment of adrenocortical function in dogs, were released on the German market. [1] In 2020, one novel pharmaceutical agent for horses or food-producing animals was released on the German market, rendering the inhaled glucocorticoid ciclesonide (Aservo EquiHaler®) available for horses for the first time. [2]2020年，一种用于小动物的新型药剂——用于评估犬肾上腺皮质功能的促肾上腺皮质激素类似物四糖酯在德国市场上市。 [1] 2020年，一种用于马或食用动物的新型药剂在德国市场上发布，使吸入性糖皮质激素环索奈德（Aservo EquiHaler®）首次用于马。 [2]
Designing Novel Pharmaceutical 设计新药
The new form of cholecalciferol would be better designing novel pharmaceutical formulations that might be more stable and more efficacious for the prevention and treatment of various diseases such as vitamin D deficiency, rickets, osteoporosis, arthritis, multiple sclerosis, cancer, diabetes mellitus, mental disorders, cardiovascular diseases, hypertension, infections, influenza, cognitive impairment in older adults, Parkinson’s and Alzheimer’s diseases, autoimmune disease, dementia, glucose intolerance, multiple sclerosis, etc. [1] Insights gained from the application of polyphasic linkage concepts should be useful for designing novel pharmaceutical ligands to regulate condensates. [2]新形式的胆钙化醇将更好地设计新的药物配方，可能更稳定、更有效地预防和治疗各种疾病，如维生素 D 缺乏症、佝偻病、骨质疏松症、关节炎、多发性硬化症、癌症、糖尿病、精神障碍、心血管疾病、高血压、感染、流感、老年人认知障碍、帕金森和阿尔茨海默病、自身免疫性疾病、痴呆、葡萄糖耐受不良、多发性硬化等。 [1] 从应用多相连接概念中获得的见解应该有助于设计新的药物配体来调节缩合物。 [2]
novel pharmaceutical agent 新型药剂
In 2020, one novel pharmaceutical agent for small animals, the ACTH analog tetracosactide for the assessment of adrenocortical function in dogs, were released on the German market. [1] This includes several newly developed methods for preparation of the implant including endotoxin removal, appropriate sterilization of raw materials, formulation of novel pharmaceutical agents, and loading of agents into drug delivery reservoirs. [2] Nutritional supplements and novel pharmaceutical agents including magnolol, flucoidan and Anamorelin are currently undergoing investigation for their potential use in BCa patients with cachexia. [3] Substantial clinical and research efforts are being invested to develop novel pharmaceutical agents. [4] EXPERT OPINION Current approaches in stroke treatment and stroke prevention have already transformed stroke care from a linear one-for-all treatment paradigm to a more individualized approach that targets specific patient subgroups with novel pharmaceutical agents. [5] The results demonstrate that certain medicinal plants have a high antiviral potential and may serve as a lead to develop novel pharmaceutical agents to cure PED as well as the diseases caused by other coronaviruses. [6] Novel pharmaceutical agents including biologics targeting various cytokines (IL-4, IL-13, IL-31, and IL-22), Janus kinase inhibitors, phosphodiesterase 4 inhibitors, and histamine H4 receptor antagonists have been approved or are being developed. [7] In 2020, one novel pharmaceutical agent for horses or food-producing animals was released on the German market, rendering the inhaled glucocorticoid ciclesonide (Aservo EquiHaler®) available for horses for the first time. [8] Despite the recent introduction of novel pharmaceutical agents in hemato-oncology, few advancements have been made in AML for decades. [9] Incorporation of the fluoromethyl group can profoundly influence the physicochemical properties of organic molecules, offering a promising strategy for the discovery of novel pharmaceutical agents. [10] An appreciation of these differences can be utilized by novel pharmaceutical agents discussed below designed to treat specific cancers. [11] The results suggest that these nanoparticles can be useful drug transport and release systems for the design of novel pharmaceutical agents for brain therapy. [12] Therefore, SHQA may be used as a novel pharmaceutical agent to combat obesity and associated metabolic syndrome. [13] In this review, we shall particularly summarize those successful research on secondary metabolites produced by deep-sea derived microorganisms with inclusion of structural characteristics, biological activities, together with biogenetic origins and taxonomic features of the source microorganisms, from which, we expect to provide more comprehensive understanding of small molecules obtained from deep-sea environment and benefit the ongoing scholarly endeavors in searching for novel pharmaceutical agents from the deep-sea derived microorganisms. [14]2020年，一种用于小动物的新型药剂——用于评估犬肾上腺皮质功能的促肾上腺皮质激素类似物四糖酯在德国市场上市。 [1] 这包括几种新开发的用于制备植入物的方法，包括去除内毒素、对原材料进行适当灭菌、新型药剂的配制以及将药剂装载到药物输送容器中。 [2] 营养补充剂和新型药剂，包括厚朴酚、氟可依丹和 Anamorelin，目前正在研究它们在患有恶病质的 BCa 患者中的潜在用途。 [3] 大量的临床和研究工作正投入到开发新的药剂中。 [4] 专家意见 当前中风治疗和中风预防的方法已经将中风护理从线性的单一治疗模式转变为更加个性化的方法，该方法针对特定患者亚组和新型药物。 [5] 结果表明，某些药用植物具有很高的抗病毒潜力，可以作为开发新的药物来治疗 PED 以及其他冠状病毒引起的疾病的线索。 [6] 包括靶向各种细胞因子（IL-4、IL-13、IL-31 和 IL-22）的生物制剂、Janus 激酶抑制剂、磷酸二酯酶 4 抑制剂和组胺 H4 受体拮抗剂在内的新型药剂已获批准或正在开发中。 [7] 2020年，一种用于马或食用动物的新型药剂在德国市场上发布，使吸入性糖皮质激素环索奈德（Aservo EquiHaler®）首次用于马。 [8] 尽管最近在血液肿瘤学中引入了新的药剂，但几十年来在 AML 方面几乎没有取得任何进展。 [9] nan [10] 下文讨论的用于治疗特定癌症的新型药剂可以利用对这些差异的认识。 [11] 结果表明，这些纳米颗粒可以作为有用的药物转运和释放系统，用于设计用于脑治疗的新型药物。 [12] nan [13] nan [14]
novel pharmaceutical formulation 新型药物配方
In the recent years, progress in nanotechnology has significantly contributed to the development of novel pharmaceutical formulations to overcome the drawbacks of conventional treatments and improve the therapeutic outcome in many diseases, especially cancer. [1] The new form of cholecalciferol would be better designing novel pharmaceutical formulations that might be more stable and more efficacious for the prevention and treatment of various diseases such as vitamin D deficiency, rickets, osteoporosis, arthritis, multiple sclerosis, cancer, diabetes mellitus, mental disorders, cardiovascular diseases, hypertension, infections, influenza, cognitive impairment in older adults, Parkinson’s and Alzheimer’s diseases, autoimmune disease, dementia, glucose intolerance, multiple sclerosis, etc. [2] Development of novel pharmaceutical formulations may overcome these barriers and imparts therapeutic levels in eye. [3] While the microgravity conditions may not be avoided in space, the suggested approaches deal with the radiation-induced modifications in humans, bacteria and medicines onboard, which may be fought by novel pharmaceutical formulation strategies along with radioprotective packaging and storage. [4] Furthermore, novel pharmaceutical formulations of older agents (e. [5] The overall results suggest that the inclusion complexes with β-CD and HP-β-CD may be potentially useful in the preparation of novel pharmaceutical formulations containing dronedarone hydrochloride. [6] We consider the type of nanosystems, their importance in a health context, the physicochemical techniques used to show the quality of these systems and their potential for the development of novel pharmaceutical formulations. [7]近年来，纳米技术的进步极大地促进了新型药物制剂的开发，以克服常规治疗的缺点并改善许多疾病，特别是癌症的治疗结果。 [1] 新形式的胆钙化醇将更好地设计新的药物配方，可能更稳定、更有效地预防和治疗各种疾病，如维生素 D 缺乏症、佝偻病、骨质疏松症、关节炎、多发性硬化症、癌症、糖尿病、精神障碍、心血管疾病、高血压、感染、流感、老年人认知障碍、帕金森和阿尔茨海默病、自身免疫性疾病、痴呆、葡萄糖耐受不良、多发性硬化等。 [2] nan [3] nan [4] nan [5] 总体结果表明，与 β-CD 和 HP-β-CD 的包合物可能潜在地用于制备含有盐酸决奈达隆的新型药物制剂。 [6] 我们考虑了纳米系统的类型、它们在健康方面的重要性、用于显示这些系统质量的物理化学技术以及它们在开发新型药物制剂方面的潜力。 [7]
novel pharmaceutical compound 新型药物化合物
Although terrestrial medicinal plants have been the focus for the development of NPs, however, in the last three decades, marine origins that include invertebrates, plants, algae, and bacteria have unearthed numerous novel pharmaceutical compounds, generally referred as marine NPs and are evolving continuously as discipline in the molecular targeted drug discovery with the inclusion of advanced screening tools which revolutionized and became the component of antitumor modern research. [1] He had worked for a pharmaceutical company for over 10 years, creating novel pharmaceutical compounds. [2] We have generated predictive models to help to assess the likelihood of ADRs in testing novel pharmaceutical compounds. [3] For this purpose, herein, the related studies designed novel pharmaceutical compounds for direct and indirect inhibition of MMP-9 as treatment approaches for DES were reviewed. [4] Although human history depicts the use of marine floras as medicine and nutrient supplement, the search for novel pharmaceutical compounds has mostly been limited to terrestrial floras. [5] Furthermore, cold-water corals may be used as paleoclimate indicators, and act as sources for novel pharmaceutical compounds as well as represent significant sinks for CO2 sequestration. [6] The ability to create disease models in a small NHP and test small quantities of novel pharmaceutical compounds early in drug development has proven especially useful in certain drug discovery and development programs. [7]尽管陆生药用植物一直是 NPs 开发的重点，然而，在过去的三十年里，包括无脊椎动物、植物、藻类和细菌在内的海洋来源已经发现了许多新的药物化合物，通常被称为海洋 NPs，并且正在不断发展作为分子靶向药物发现的学科，包含先进的筛选工具，彻底改变并成为抗肿瘤现代研究的组成部分。 [1] 他在一家制药公司工作了 10 多年，创造了新的药物化合物。 [2] 我们已经生成了预测模型，以帮助评估在测试新型药物化合物时出现 ADR 的可能性。 [3] nan [4] 尽管人类历史描述了海洋植物群作为药物和营养补充剂的用途，但对新型药物化合物的探索大多仅限于陆地植物群。 [5] 此外，冷水珊瑚可用作古气候指标，并作为新型药物化合物的来源，以及代表二氧化碳封存的重要汇。 [6] nan [7]
novel pharmaceutical strategy
This study lays the grounds for further investigations insight novel pharmaceutical strategies targeting key effectors involved in the molecular cascade triggered by HA. [1] J Biochem 2017;161:99-111) showed a specific glycosylation at a site proximal to the β-secretase cleavage site and decreased productions of Aβ1-40 and Aβ1-42 in HEK293T cells transfected with a particular mucin-type glycan initiation enzyme, GalNAc-T6, indicating a novel pharmaceutical strategy to inhibit the production of Aβ through the upregulation of mucin-type O-glycosylation. [2] Therefore, novel pharmaceutical strategies to optimize the pharmacotherapy of Chagas disease are urgently required. [3] For the molecular drug development, safe-by-design has become as a novel pharmaceutical strategy that allows a reduction of the costs and an acceleration of the translation of research to market. [4] In summary, BBR combined with Sta produced better glycometabolism than BBR alone through modulating gut microbiota and fecal metabolomics, and may aid in the development of a novel pharmaceutical strategy for treating Type 2 diabetes mellitus. [5]这项研究为进一步研究深入了解针对 HA 触发的分子级联中涉及的关键效应物的新药物策略奠定了基础。 [1] J Biochem 2017;161:99-111) 在转染特定粘蛋白型聚糖起始酶的 HEK293T 细胞中，在靠近 β-分泌酶切割位点的位点显示出特异性糖基化，并且 Aβ1-40 和 Aβ1-42 的产生减少， GalNAc-T6，表明一种通过上调粘蛋白型 O-糖基化来抑制 Aβ 产生的新药物策略。 [2] nan [3] nan [4] nan [5]
novel pharmaceutical dosage
An option to avoid toxicity is represented by the targeted cancer treatment using novel pharmaceutical dosage forms. [1] Overall, the obtained data confirmed that the inclusion complexes prepared by kneading followed by spray-drying, especially those based on HP-β-CD, appeared to be the most promising formulations and, therefore, could be encouragingly explored in the development of novel pharmaceutical dosage forms containing DRO, presumably with reduced side effects and improved safety profile. [2] This review aims to provide an explanation of normal vaginal microbiota, the factors that modify it, its involvement in the administration of drugs, and new proposals for the design of novel pharmaceutical dosage forms. [3] However, solubility tests for isolated components indicates the need for novel pharmaceutical dosage forms, in the case for using natural flavonoids as chemotherapeutic agents. [4]避免毒性的一种选择是使用新型药物剂型进行靶向癌症治疗。 [1] 总体而言，获得的数据证实，通过捏合和喷雾干燥制备的包合物，尤其是基于 HP-β-CD 的包合物，似乎是最有前途的制剂，因此可以在开发新药时受到鼓舞。含有 DRO 的剂型，可能具有减少的副作用和提高的安全性。 [2] 这篇综述旨在解释正常阴道微生物群、改变它的因素、其参与药物给药以及设计新药物剂型的新建议。 [3] nan [4]
novel pharmaceutical excipient 新型药用辅料
According to the physicochemical properties, especially high swelling ability and high viscosity nature, dried DIMs showed the possibility to be a novel pharmaceutical excipient. [1] Moreover, the data intelligence modeling demonstrates the reliability and satisfactory of ANFIS as a hybrid model over the other two models with increased performance skills in modeling the compaction properties of these novel pharmaceutical excipients. [2] Ongoing demand in sustainable and biocompatible drug dosage forms is reflected in the search for novel pharmaceutical excipients with equal properties. [3] The internal structure of the novel pharmaceutical excipient, functionalized calcium carbonate, was revealed for the first time. [4]根据物理化学性质，特别是高溶胀能力和高粘度性质，干燥的DIMs显示出成为一种新型药用辅料的可能性。 [1] 此外，数据智能建模证明了 ANFIS 作为混合模型的可靠性和令人满意的结果，与其他两种模型相比，在模拟这些新型药用辅料的压实特性方面具有更高的性能技能。 [2] 对可持续和生物相容性药物剂型的持续需求反映在寻找具有相同特性的新型药用辅料上。 [3] 首次揭示了新型药用辅料功能化碳酸钙的内部结构。 [4]
novel pharmaceutical target
Characterisation of microRNAs that produce an effect on neurological activity, such as miR-324, and identification of the pathways they regulate will allow a better understanding of the processes involved in normal neurological function and in turn may present novel pharmaceutical targets in treating neurological disease. [1] Conclusion This study further supports OTRs as a novel pharmaceutical target for drug delivery. [2] Current research in the field of ischemic stroke focuses on better understanding the pathophysiology of stroke, to develop and investigate novel pharmaceutical targets. [3] This study further supports oxytocin receptors as a novel pharmaceutical target for drug delivery to the uterus. [4]对神经活动产生影响的 microRNA 的表征，如 miR-324，以及它们调节的途径的鉴定，将有助于更好地了解正常神经功能所涉及的过程，进而可能为治疗神经疾病提供新的药物靶点。 [1] 结论 本研究进一步支持 OTR 作为药物递送的新型药物靶点。 [2] 目前缺血性中风领域的研究重点是更好地了解中风的病理生理学，以开发和研究新的药物靶点。 [3] nan [4]
novel pharmaceutical product
Use of plants among the two tribes reflects their interest in ethno-medicine and further investigation on under-explored species may lead to the discovery of novel pharmaceutical products. [1] Chalcones and flavonoids constitute a large family of plant secondary metabolites that have been explored as a potential source of novel pharmaceutical products. [2] OBJECTIVE To identify and assess the methods for estimating comparative clinical effectiveness for novel pharmaceutical products licensed on the basis of nonrandomized controlled trial (non-RCT) data and to evaluate the corresponding National Institute for Health and Care Excellence (NICE) recommendations. [3] This useful information could help in producing potentially valuable and novel pharmaceutical products. [4]这两个部落对植物的使用反映了他们对民族医学的兴趣，对未开发物种的进一步调查可能会导致发现新的医药产品。 [1] 查尔酮和类黄酮构成了一大类植物次生代谢物，已被探索为新型药物产品的潜在来源。 [2] 客观的 根据非随机对照试验 (non-RCT) 数据确定和评估评估新药品的比较临床有效性的方法，并评估相应的国家健康与护理卓越研究所 (NICE) 建议。 [3] nan [4]
novel pharmaceutical lead 新药先导
(+)-Albaconol, (+)-neoalbaconol and two yahazunol isomers (24 and 25) were witnessed to be the novel pharmaceutical leads. [1] (+)-Albaconol, (+)-neoalbaconol, and two (+)-yahazunol isomers (24 and 25) proved to be the novel pharmaceutical leads. [2] Therefore, these compounds can be taken into account as candidates for the development of effective and novel pharmaceutical leads. [3] It also brings direct evidence that cyanobacterial strain axenization can lead to a rapid decrease in production of valuable compounds and that non-axenic strains may be considered more suitable for retrieval and initial production of novel pharmaceutical leads. [4](+)-Albaconol、(+)-neoalbaconol 和两种 yahazunol 异构体（24 和 25）被证明是新的药物先导物。 [1] (+)-Albaconol、(+)-neoalbaconol 和两种 (+)-yahazunol 异构体（24 和 25）被证明是新的药物先导化合物。 [2] nan [3] 它还提供了直接证据，表明蓝藻菌株轴化可导致有价值化合物的产量迅速减少，并且非轴化菌株可能被认为更适合检索和初始生产新的药物先导物。 [4]
novel pharmaceutical technology 新型制药技术
Poly-Ethylene-Glycol (PEG) attachment is a novel pharmaceutical technology to improve the efficacy and safety of chemotherapies. [1] The major concern is about the possible occurrence of adverse effects, particularly in the context of the use of novel pharmaceutical technologies such as mRNA. [2] "Supramolecular pharmaceutical sciences" could encompass strictly controlled molecular arrangement, stimulus responsible molecular motion, new functions beyond those of existing molecules, more accurate drug design, new active pharmaceutical ingredients, new perspectives for the investigation of the drug mechanisms, and novel pharmaceutical technologies. [3]聚乙二醇 (PEG) 附件是一种提高疗效的新型制药技术 和化疗的安全性。 [1] 主要关注的是可能发生的不良反应，特别是在使用新型制药技术（如 mRNA）的情况下。 [2] “超分子药物科学”可以包括严格控制的分子排列、刺激负责任的分子运动、超越现有分子的新功能、更精确的药物设计、新的活性药物成分、研究药物机制的新视角以及新的制药技术。 [3]
novel pharmaceutical drug
Special consideration is given to inhibitors of these enzymes and their role as potential new antifungals and emerging tools for the discovery of novel pharmaceutical drugs and antibiotics in fungal producer strains. [1] The discovery of novel materials and functional molecules can help to solve some of society's most urgent challenges, ranging from efficient energy harvesting and storage to uncovering novel pharmaceutical drug candidates. [2] Significance Statement During the development of a novel pharmaceutical drug, in vitro studies are conducted to assess the risk of potential adverse interactions between existing medications a patient may already be taking and the novel compound. [3]特别考虑了这些酶的抑制剂及其作为潜在的新抗真菌剂和新兴工具的作用，用于在真菌生产菌株中发现新型药物和抗生素。 [1] 新材料和功能分子的发现有助于解决一些社会最紧迫的挑战，从有效的能量收集和储存到发现新的候选药物。 [2] 意义声明 在开发新型药物期间，进行体外研究以评估患者可能已经服用的现有药物与新型化合物之间潜在不良相互作用的风险。 [3]
novel pharmaceutical therapy
Advanced in vitro models, which closely mimic critical aspects of the pathology, have emerged as valuable platforms to investigate novel pharmaceutical therapies for the treatment of SSc. [1] The discovery and development of novel pharmaceutical therapies is rapidly transitioning from a small molecule–dominated focus to a more balanced portfolio consisting of small molecules, monoclonal antibodies, engineered proteins (modified endogenous proteins, bispecific antibodies, and fusion proteins), oligonucleotides, and gene-based therapies. [2] Understanding the biological basis for this condition may provide necessary insight for development of novel pharmaceutical therapies or risk prediction. [3]先进的体外模型密切模仿病理学的关键方面，已成为研究治疗 SSc 的新型药物疗法的宝贵平台。 [1] 新型药物疗法的发现和开发正在迅速从以小分子为主导的焦点转变为由小分子、单克隆抗体、工程蛋白（修饰的内源蛋白、双特异性抗体和融合蛋白）、寡核苷酸和基因组成的更平衡的产品组合为基础的疗法。 [2] 了解这种情况的生物学基础可能为开发新的药物疗法或风险预测提供必要的见解。 [3]
novel pharmaceutical intervention 新型药物干预
In sum, our novel zebrafish model of liver steatosis and steatohepatitis is a promising model in which to study the intricate associations between NAFLD and T2D, and may serve as an amenable platform for screening novel pharmaceutical interventions. [1] There is a pressing need for novel pharmaceutical interventions for the major neuropsychiatric diseases schizophrenia (SCZ), bipolar disorder (BPD), major depressive disorder (MDD), and autism spectrum disorder (ASD). [2] This may make ESC-derived tenocytes an advantageous source of cells for tissue regeneration and allow the development of novel pharmaceutical interventions to protect endogenous cells from inflammation. [3]总之，我们的新型肝脂肪变性和脂肪性肝炎斑马鱼模型是研究 NAFLD 和 T2D 之间复杂关联的有前景的模型，并且可以作为筛选新型药物干预措施的合适平台。 [1] 迫切需要针对主要神经精神疾病精神分裂症 (SCZ)、双相情感障碍 (BPD)、重度抑郁症 (MDD) 和自闭症谱系障碍 (ASD) 进行新型药物干预。 [2] 这可能使 ESC 衍生的肌腱细胞成为组织再生的有利细胞来源，并允许开发新的药物干预措施以保护内源性细胞免受炎症。 [3]
novel pharmaceutical application
This review offers an in-depth insight into its novel Pharmaceutical applications as well as sources, processing, physicochemical properties, and nutritional and physiological activities. [1] Microbes have been explored as a potential source of bioactive compounds for novel pharmaceutical applications. [2] Their involvement in maintenance and repair processes of various tissues and organs made these growth factors highly interesting targets for novel pharmaceutical applications in regenerative medicine. [3]nan [1] 微生物已被探索为用于新型药物应用的生物活性化合物的潜在来源。 [2] 它们参与各种组织和器官的维护和修复过程，使这些生长因子成为再生医学中新型药物应用的非常有趣的目标。 [3]
novel pharmaceutical form 新型药物形式
The obtained results demonstrate the high potential of flavonoids Qu and Rut to the development of novel pharmaceutical forms using the example of Camphecene in the form of molecular complexes, as the novel forms of delivery. [1] In future, the inclusion of allantoin-rich extracts in various novel pharmaceutical forms for new therapeutic applications could be achieved. [2] After further tests we believe that NLC-CIP can come to be a novel pharmaceutical form to potentiate the antibiotic effect, reducing its dosage and undesirable side effects. [3]所获得的结果证明了黄酮类化合物 Qu 和 Rut 在开发新的药物形式方面的巨大潜力，使用分子复合物形式的樟脑作为新的递送形式。 [1] 将来，可以实现将富含尿囊素的提取物包含在各种新的药物形式中，用于新的治疗应用。 [2] nan [3]
novel pharmaceutical manufacturing
All results of this paper clearly reveal the feasibility and capability of SSE 3D printing technology as a novel pharmaceutical manufacturing technique to fabricate personalized medicines and modulate drug dissolution profiles. [1] All the results demonstrated the potential and capability of semi-solid extrusion 3-dimensional printing as a novel pharmaceutical manufacturing technique to provide a dynamic and highly accurate controllable system for preparing patient-tailored medicines. [2]本文的所有结果清楚地揭示了 SSE 3D 打印技术作为一种新型药物制造技术来制造个性化药物和调节药物溶出曲线的可行性和能力。 [1] 所有结果都证明了半固态挤出 3D 打印作为一种新型药物制造技术的潜力和能力，可为制备患者定制药物提供动态且高度准确的可控系统。 [2]
novel pharmaceutical development 新药开发
BK channels may also offer other potentially broad and underrecognized promising targets for novel pharmaceutical development. [1] Proteomic analyses of intervertebral discs (IVDs) reveal information for understanding the fundamentals of biological processes and pathogenesis but also provide insights for novel pharmaceutical development. [2]BK 通道还可能为新药开发提供其他潜在广泛且未被充分认识的有希望的目标。 [1] 椎间盘 (IVD) 的蛋白质组学分析揭示了了解生物过程和发病机制的基本原理的信息，同时也为新型药物开发提供了见解。 [2]